Renal safety and clinical outcomes of enfortumab vedotin plus pembrolizumab in urothelial carcinoma patients with chronic kidney disease.
Parth Dhamelia(University of Arkansas for Medical Sciences), Karan Jatwani(Roswell Park Comprehensive Cancer Center), Atulya Aman Khosla(Baptist Hospital of Miami), Nitya Batra(Jacksonville College), Yagnapriya Ammakola(Beaumont Hospital, Troy), Mohammad Arfat Ganiyani(Baptist Hospital of Miami), Rohan Garje(Miami Heart Research Institute), M Pustake(Texas Tech University), Nishank Jain(Rochester General Hospital)
Cited by 0
Related Papers
Early Detection of Subclinical Visual Damage After Blast-Mediated TBI Enables Prevention of Chronic Visual Deficit by Treatment With P7C3-S243
|Investigative Ophthalmology & Visual Science|2014|91
Toxoplasmosis in organ transplant recipients: Evaluation, implication, and prevention
|Tropical parasitology|2016|80
COVID-19 Infection and Myocarditis: A State-of-the-Art Systematic Review
|Journal of Primary Care & Community Health|2021|48
Diagnostic potential of multi‐targeted LAMP (loop‐mediated isothermal amplification) for osteoarticular tuberculosis
|Journal of Orthopaedic Research®|2016|44
Depression and Its Effect on the Menstrual Cycle
|Cureus|2021|43